

Comparison of the effect of anti-hypertensive treatment with verapamil and amlodipine on the coronary vasodilator reserve and the transmural distribution of myocardial blood flow in hypertensive patients with left ventricular hypertrophy

Submission date 13/09/2005	Recruitment status No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
Registration date 04/11/2005	Overall study status Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
Last Edited 20/05/2016	Condition category Circulatory System	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Prof Paolo Camici

Contact details
MRC CSC
Hammersmith Campus
London
United Kingdom
W12 0NN

Additional identifiers

Protocol serial number
VER240/1/01

Study information

Scientific Title

Comparison of the effect of anti-hypertensive treatment with verapamil and amlodipine on the coronary vasodilator reserve and the transmural distribution of myocardial blood flow in hypertensive patients with left ventricular hypertrophy

Study objectives

Beneficial effect of calcium antagonists on coronary vasodilator reserve and transmural distribution of flow in hypertensive patients with left ventricular hypertrophy.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Study type(s)

Treatment

Health condition(s) or problem(s) studied

Hypertension

Interventions

The study will enrol hypertensive patients with a left ventricular septum thickness of 13 mm measured with 2D echocardiogram. The overall duration of the study will be of 13 weeks. The first week will consist of a wash-out/run-in phase, when only diuretic therapy will be allowed.

Thereafter the patients will be assigned following the randomisation list to the double-blinded treatment (group 1: verapamil or matching placebo; group 2: amlodipine or matching placebo).

After a period of 6 weeks of treatment the first positron emission tomography (PET) scan will be performed.

Afterwards, within each group, patients will change double-blind treatment from active drug to matching placebo or vice-versa, for 6 additional weeks at the end of which the second and final PET scan will be performed.

The primary parameter under study i.e. myocardial blood flow, will be measured at rest and after the dipyridamole stress test at the end of each treatment period. Briefly, a radioisotope of water ($H_2^{15}O$) will be infused through a peripheral vein, subsequently, with the patient lying flat, the scan will be acquired. Once this is completed, dipyridamole is infused via the same

catheter for 4 minutes. At the end of the infusion, a further scan with $H_2^{15}O$ will be undertaken. The whole procedure will last approximately 90 minutes. Any treatment for hypertension, except for thiazidic diuretics and phtalimidine derivatives, will not be allowed.

Intervention Type

Drug

Phase

Not Specified

Drug/device/biological/vaccine name(s)

Verapamil, amlodipine

Primary outcome(s)

The primary objective of the study is to compare the Coronary Vasodilator Reserve corrected after treatment with verapamil, placebo and amlodipine in hypertensive subjects with left ventricular hypertrophy. With two treatments, two measurements and a within-subject control.

Key secondary outcome(s)

Reduction of left ventricular mass

Completion date

31/01/2005

Eligibility**Key inclusion criteria**

1. Blood pressure (measured after 5 minutes in the supine position) 160/100 mmHg based on the mean of 3 recordings within a 1 minute interval
2. Left ventricular septum thickness ≥ 13 mm or left ventricular mass index (LVMI) ≥ 130 g/m² (men), ≥ 100 g/m² (women). The measurements will be recorded by echocardiography.

Participant type(s)

Patient

Healthy volunteers allowed

No

Age group

Adult

Sex

All

Key exclusion criteria

1. Women of childbearing age without adequate contraception
2. Any documented disease of any of the following systems will be a contraindication to entry into the study: respiratory, renal, digestive, nervous central or peripheral, musculoskeletal, haemolymphopoietic, immune, metabolism
3. Subjects with drug or alcohol addiction

Date of first enrolment

01/03/1998

Date of final enrolment

31/01/2005

Locations

Countries of recruitment

United Kingdom

England

Study participating centre

MRC CSC

London

United Kingdom

W12 0NN

Sponsor information

Organisation

Abbott (Germany)

ROR

<https://ror.org/02x2gk324>

Funder(s)

Funder type

Industry

Funder Name

Abbott (Germany)

Results and Publications

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration